MX2023003463A - Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. - Google Patents
Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.Info
- Publication number
- MX2023003463A MX2023003463A MX2023003463A MX2023003463A MX2023003463A MX 2023003463 A MX2023003463 A MX 2023003463A MX 2023003463 A MX2023003463 A MX 2023003463A MX 2023003463 A MX2023003463 A MX 2023003463A MX 2023003463 A MX2023003463 A MX 2023003463A
- Authority
- MX
- Mexico
- Prior art keywords
- taa
- antigen
- cell receptors
- same against
- recognizing constructs
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 abstract 2
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464489—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención atañe a constructos reconocedores de antígeno dirigidos contra antígenos asociados a tumores (TAA), en particular contra el antígeno expresado preferencialmente en el melanoma (PRAME, por sus siglas en inglés). La invención proporciona en concreto moléculas basadas en un nuevo receptor de linfocitos T (TCR) que son selectivas y específicas hacia el antígeno de la invención que es expresado por tumores. El TCR de la invención, así como los fragmentos de unión con el TAA que derivan del mismo, están destinados al uso en el diagnóstico, el tratamiento y la prevención de enfermedades tumorales que expresan el TAA. Además, se proporcionan ácidos nucleicos que codifican los constructos reconocedores del antígeno de la invención, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan los constructos reconocedores del antígeno y las composiciones farmacéuticas que comprenden los compuestos de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475329P | 2017-03-23 | 2017-03-23 | |
| DE102017106305.6A DE102017106305A1 (de) | 2017-03-23 | 2017-03-23 | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003463A true MX2023003463A (es) | 2023-04-19 |
Family
ID=61899213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011260A MX2019011260A (es) | 2017-03-23 | 2018-03-23 | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. |
| MX2023003463A MX2023003463A (es) | 2017-03-23 | 2019-09-20 | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011260A MX2019011260A (es) | 2017-03-23 | 2018-03-23 | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11236145B2 (es) |
| EP (2) | EP3600409B1 (es) |
| JP (2) | JP2020511152A (es) |
| KR (1) | KR20190132655A (es) |
| CN (1) | CN110494160B (es) |
| AU (1) | AU2018240501A1 (es) |
| BR (1) | BR112019019523A2 (es) |
| CA (1) | CA3056493A1 (es) |
| CL (1) | CL2019002645A1 (es) |
| CO (1) | CO2019011688A2 (es) |
| CR (1) | CR20190482A (es) |
| DK (1) | DK3600409T3 (es) |
| FI (1) | FI3600409T3 (es) |
| IL (2) | IL310552A (es) |
| LT (1) | LT3600409T (es) |
| MX (2) | MX2019011260A (es) |
| PE (1) | PE20191493A1 (es) |
| PH (1) | PH12019502151A1 (es) |
| PT (1) | PT3600409T (es) |
| SG (1) | SG11201908023YA (es) |
| TW (1) | TWI799922B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| KR20210130189A (ko) | 2019-02-20 | 2021-10-29 | 프레드 헛친슨 켄서 리서치 센터 | Ras 신항원에 특이적인 결합 단백질 및 이의 용도 |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| CA3139508A1 (en) * | 2019-05-08 | 2020-11-12 | Janssen Biotech, Inc. | Materials and methods for modulating t cell mediated immunity |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| CA3168729A1 (en) | 2020-02-24 | 2021-09-02 | Melinda MATA | Methods for expanding t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022017435A1 (zh) * | 2020-07-22 | 2022-01-27 | 信达生物制药(苏州)有限公司 | 一系列TCR-β链的CDR3序列中共有序列的生物标志物及其应用 |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| CA3203118A1 (en) | 2020-12-31 | 2022-07-07 | Gagan BAJWA | Cd8 polypeptides, compositions, and methods of using thereof |
| AU2022270361A1 (en) | 2021-05-05 | 2023-11-16 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| CA3225252A1 (en) | 2021-07-14 | 2023-01-19 | Jordan JARJOUR | Engineered t cell receptors fused to binding domains from antibodies |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
| CN113789304B (zh) * | 2021-10-14 | 2023-03-31 | 深圳大学总医院 | 高亲和力tcr及其应用 |
| CN113817044B (zh) * | 2021-10-14 | 2023-10-13 | 深圳大学总医院 | T细胞受体、相关工程化细胞及其应用 |
| EP4448108A1 (en) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115073584B (zh) * | 2022-05-07 | 2023-10-20 | 溧阳瑅赛生物医药有限公司 | 一种特异性识别prame抗原肽的tcr及其应用 |
| CN116813744B (zh) * | 2023-02-23 | 2024-02-23 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2839663A1 (en) | 2011-06-28 | 2013-01-03 | International Institute Of Cancer Immunology, Inc. | Receptor gene for peptide cancer antigen-specific t cell |
| RU2578009C2 (ru) | 2013-05-08 | 2016-03-20 | Закрытое акционерное общество "ЕВРОГЕН" | Способ идентификации нативных пар фрагментов днк или рнк, присутствующих в одних и тех же живых клетках |
| KR20170032406A (ko) | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
| JP2018510627A (ja) | 2015-03-10 | 2018-04-19 | レイデン ユニバーシティ メディカル センター | メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用 |
| EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
| CA2986713A1 (en) | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
| CN106084036A (zh) | 2015-11-02 | 2016-11-09 | 广州市香雪制药股份有限公司 | 识别prame抗原短肽的t细胞受体 |
| CN106519019B (zh) | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | 识别prame抗原的tcr |
| CN106478809B (zh) | 2015-11-06 | 2018-06-01 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的tcr |
| CN106831978B (zh) | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原的t细胞受体 |
| CN106699874B (zh) | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的t细胞受体 |
| ES2949342T3 (es) | 2016-06-17 | 2023-09-27 | Medigene Immunotherapies Gmbh | Receptores de células T y usos de los mismos |
| DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
-
2018
- 2018-03-22 US US15/928,785 patent/US11236145B2/en active Active
- 2018-03-23 MX MX2019011260A patent/MX2019011260A/es unknown
- 2018-03-23 LT LTEPPCT/EP2018/057482T patent/LT3600409T/lt unknown
- 2018-03-23 SG SG11201908023Y patent/SG11201908023YA/en unknown
- 2018-03-23 FI FIEP18715559.3T patent/FI3600409T3/fi active
- 2018-03-23 KR KR1020197030006A patent/KR20190132655A/ko not_active IP Right Cessation
- 2018-03-23 IL IL310552A patent/IL310552A/en unknown
- 2018-03-23 TW TW110126772A patent/TWI799922B/zh active
- 2018-03-23 PT PT187155593T patent/PT3600409T/pt unknown
- 2018-03-23 PE PE2019001902A patent/PE20191493A1/es unknown
- 2018-03-23 BR BR112019019523A patent/BR112019019523A2/pt unknown
- 2018-03-23 CA CA3056493A patent/CA3056493A1/en active Pending
- 2018-03-23 IL IL269578A patent/IL269578B2/en unknown
- 2018-03-23 CR CR20190482A patent/CR20190482A/es unknown
- 2018-03-23 EP EP18715559.3A patent/EP3600409B1/en active Active
- 2018-03-23 JP JP2019552175A patent/JP2020511152A/ja active Pending
- 2018-03-23 DK DK18715559.3T patent/DK3600409T3/da active
- 2018-03-23 AU AU2018240501A patent/AU2018240501A1/en active Pending
- 2018-03-23 CN CN201880019206.5A patent/CN110494160B/zh active Active
- 2018-03-23 EP EP24194122.8A patent/EP4450087A2/en active Pending
-
2019
- 2019-09-16 CL CL2019002645A patent/CL2019002645A1/es unknown
- 2019-09-19 PH PH12019502151A patent/PH12019502151A1/en unknown
- 2019-09-20 MX MX2023003463A patent/MX2023003463A/es unknown
- 2019-10-22 CO CONC2019/0011688A patent/CO2019011688A2/es unknown
-
2021
- 2021-12-16 US US17/553,017 patent/US20220098270A1/en active Pending
-
2023
- 2023-03-20 JP JP2023044130A patent/JP2023088973A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220098270A1 (en) | 2022-03-31 |
| FI3600409T3 (fi) | 2024-09-03 |
| IL269578A (en) | 2019-11-28 |
| EP3600409A2 (en) | 2020-02-05 |
| US11236145B2 (en) | 2022-02-01 |
| PE20191493A1 (es) | 2019-10-21 |
| JP2020511152A (ja) | 2020-04-16 |
| IL269578B1 (en) | 2024-03-01 |
| CN110494160B (zh) | 2024-06-25 |
| CL2019002645A1 (es) | 2019-12-13 |
| IL310552A (en) | 2024-03-01 |
| AU2018240501A1 (en) | 2019-10-31 |
| CN110494160A (zh) | 2019-11-22 |
| TWI799922B (zh) | 2023-04-21 |
| JP2023088973A (ja) | 2023-06-27 |
| CA3056493A1 (en) | 2018-09-27 |
| LT3600409T (lt) | 2024-09-10 |
| CR20190482A (es) | 2020-01-07 |
| SG11201908023YA (en) | 2019-10-30 |
| IL269578B2 (en) | 2024-07-01 |
| EP3600409B1 (en) | 2024-08-14 |
| DK3600409T3 (da) | 2024-09-09 |
| US20180273602A1 (en) | 2018-09-27 |
| EP4450087A2 (en) | 2024-10-23 |
| KR20190132655A (ko) | 2019-11-28 |
| BR112019019523A2 (pt) | 2020-04-22 |
| MX2019011260A (es) | 2019-12-05 |
| TW202208420A (zh) | 2022-03-01 |
| PH12019502151A1 (en) | 2020-06-29 |
| PT3600409T (pt) | 2024-09-13 |
| CO2019011688A2 (es) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003463A (es) | Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame. | |
| WO2018172533A3 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| MX2022015821A (es) | Nuevos receptores de celulas t y usos de los mismos. | |
| MX2019006724A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
| MX2019006727A (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza. | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| CR20190594A (es) | Receptores de células t novedosos, e inmunoterapia usando los mismos | |
| MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| TW201613971A (en) | Anti-epidermal growth factor receptor (EGFR) antibodies | |
| MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
| MY195101A (en) | Novel T Cell Receptors and Immune Therapy Using the Same | |
| EA202090712A1 (ru) | Новые полученные методами генной инженерии t-клеточные рецепторы и иммунная терапия с их использованием | |
| PH12019501263A1 (en) | Novel t cell receptors and immune therapy using the same | |
| EA201992002A1 (ru) | Т-клеточные рецепторы и иммунная терапия prame-положительных раковых заболеваний с их применением | |
| AR110682A1 (es) | Receptores de células t y terapia inmunológica que los utiliza | |
| AR113834A1 (es) | Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos | |
| EA201991139A1 (ru) | Новые т-клеточные рецепторы и иммунотерапия с их применением | |
| EA201990488A1 (ru) | Новые t-клеточные рецепторы и иммунотерапия с их применением |